Associate Director, Cell Therapy Account Management - East Los Angeles, CA
Kite Pharma
Summary
The Associate Director Cellular Therapy Account Manager (CTAM) has primary responsibility for developing the relationship with Kite's Authorized Treatment Centers (ATCs) and serves as the ATC's primary point of contact with Kite. In this role, the CTAM is responsible for driving appropriate utilization of Kite's CAR T therapies within the account and ensuring the delivery of a seamless customer experience.
Job description
Territory: East Los Angeles, CA. This is a field-based position based in East Los Angeles, CA. Candidates should reside within 20 miles of the geography.
Key Responsibilities
Account Ownership & Demand Generation
- Own overall performance, strategy, and execution for assigned ATCs and associated referral networks
- Drive appropriate patient identification, referral, and therapy adoption through compliant education and engagement
- Differentiate Kite CAR T therapies versus alternative options using approved messaging
- Develop and execute comprehensive account and territory plans aligned with regional and national priorities
- Deliver against defined sales goals, KPIs, and growth objectives
Stakeholder Engagement & Relationship Leadership
- Build trusted relationships with treating physicians, referrers, transplant teams, administrators, and key influencers
- Navigate complex academic and integrated delivery networks to align priorities and remove barriers to care
- Lead engagement across multiple stakeholders to support class and brand growth
- Represent Kite at scientific congresses, speaker programs, and peer to peer educational forums
Patient Access & Cell Therapy Coordination
- Identify, map, and optimize patient referral pathways within hematology and oncology networks
- Partner with cross functional peers to support patient access, reimbursement education, and logistical coordination
- Support ATC readiness and comfort with CAR T processes to enable demand generation
Cross Functional Leadership & Collaboration
- Act as the quarterback across Medical, Market Access, Operations, and ATC Onboarding teams
- Provide timely insights on account trends, competitive dynamics, and market opportunities
- Influence resource prioritization to address account specific needs and growth opportunities
- Ensure all activities are executed in compliance with company policies
Success in This Role Looks Like
- Sustained growth in referrals (Class) and treated patients (Brand)
- Strong, trusted partnerships across key stakeholders within each account
- Consistent execution of strategic account plans that drive brand and class share
- Proactive identification and resolution of access, operational, and market barriers
- High standards of compliance, professionalism, and cross functional collaboration
Requirements
- BA/BS and 10 years of experience OR MA/MS and 8 years of experience OR PhD and 2 years of experience
- MBA preferred
- Demonstrated record of successful oncology account management within an academic setting
- Deep clinical expertise in hematology/oncology disease and understanding of treatment landscape (5+ years of experience)
- Demonstrated record of successful account management in large accounts (direct or indirect line leadership experience)
- Strong clinical understanding of cell therapy and ability to manage complex treatment logistics
- Direct line leadership experience
- Customer Focus; Patient Centric
- Results Driven
- Rare Disease mindset with a proven history of perseverance and appropriate patient identification
- Strategic Thinker and ability to work in matrix environment
- Cross Functional Leadership
- Strong Business & Analytical Acumen
- Integrity, Compliance & Trust
Benefits
- Annual Bonus
- Stock-Based Long-Term Incentives
- Paid Time Off
- Medical, Dental & Vision
- Life Insurance
Company overview
Kite Pharma, Inc. is an American biotechnology company specializing in cancer immunotherapy with a primary focus on genetically engineered autologous CAR T cell therapy. Founded in 2009 and headquartered in Santa Monica, California, Kite was acquired by Gilead Sciences in 2017 for $11.9 billion. The company develops cell-based therapies that reengineer a patient's own immune cells to attack and fight cancer cells, representing a personalized approach to cancer treatment. Kite's lead product, Yescarta (axicabtagene ciloleucel), was the first CAR T therapy approved by the FDA for treating adult patients with relapsed or refractory large B-cell lymphoma. With approximately 2,000 employees and manufacturing facilities in California, Maryland, and the Netherlands, Kite operates as an independent company within Gilead Sciences while maintaining its singular focus on advancing cell therapy to treat and potentially cure cancer. The company's innovative approach represents a paradigm shift in cancer treatment, moving away from traditional pharmaceutical manufacturing to individualized cell therapies created one patient at a time.